KBC Group
CAPR icon

KBC Group’s Capricor Therapeutics CAPR Stock Holding History

KBC Group’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35K Hold
1,461
– – ﹤0.01% 1798
2026
Q1 		$44K Buy
+1,461
New +$38.9K ﹤0.01% 1689

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KBC Group's CAPR Position: Q2 2026 in Review

KBC Group held its Capricor Therapeutics (CAPR) position steady in Q2 2026 at 1,461 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #1798.

KBC Group first reported a position in CAPR in Q1 2026 and has held it in 2 quarters since. The position peaked at $44K in Q1 2026. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • KBC Group held 1,461 shares of Capricor Therapeutics worth $35K as of Q2 2026.
  • KBC Group left its Capricor Therapeutics share count unchanged in Q2 2026.
  • Capricor Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1798 holding.
  • KBC Group first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • KBC Group's Capricor Therapeutics position peaked at $44K in Q1 2026.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.